Posaconazole: a new antifungal weapon.

  title={Posaconazole: a new antifungal weapon.},
  author={Georgios Aperis and Polichronis Alivanis},
  journal={Reviews on recent clinical trials},
  volume={6 3},
The last twenty years, the incidence of invasive fungal infections (IFI) has risen dramatically due to the prolongation of survival of patients with multiple risk factors for fungal infections. Amphotericin B was for more than 40 years the gold standard for almost all IFI, but toxicity and resistance, especially of new and emerging pathogens remained important issues. Fluconazole and itraconazole have also the same disadvantage of resistance. Voriconazole, a new triazole antifungal has offered… Expand
Fusariosis in a Patient with Acute Myeloid Leukemia: A Case Report and Review of the Literature
The case of a disseminated Fusariumsolani infection in a patient with acute myeloid leukemia which never reached complete remission during its clinical course is described, resulting in the patient's clinical condition deteriorated with fatal outcome. Expand
Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study.
Posaconazole and voriconazole have the same prophylactic effect against IFDs in high-risk neutropenic Chinese patients, while in terms of cost-effectiveness, voriconsazole has an advantage over posaconazoles. Expand
Voriconazole in clinical practice
Pharmacological, mycological and clinical aspects of the treatment with voriconazole are summarized in order to optimize its use in daily clinical practice. Expand
Posaconazole versus Itraconazole as Prophylactic Antifungal Agents during Induction Chemotherapy for Acute Myeloid Leukemia: A Real-World Single Center Comparison
There was no significant difference in the incidence of IFD and 100-day mortality between the patients with induction chemotherapy for newly diagnosed AML who received posaconazoles and itraconazole as prophylactic antifungal agents. Expand
Current and future challenges in the development of antimicrobial agents.
  • R. Rennie
  • Biology, Medicine
  • Handbook of experimental pharmacology
  • 2012
Animal models and non-mammalian systems have been developed to determine if new agents will reach sufficient concentrations at infection sites to predict clinical efficacy without toxicity, and whether antimicrobial stewardship is an important component of the continuing battle to prevent the development of antimicrobial resistance. Expand
Mucormycosis (zygomycosis) of renal allograft
Renal allograft mucormycosis is a relatively rare and potentially fatal complication following renal transplantation and early diagnosis, graft nephrectomy and appropriate antifungal therapy may result in an improved prognosis for these patients. Expand
Mucormycosis and acute kidney injury.
The diagnosis of the renal mucormycosis is based on renal histology sections of renal biopsy or nephrectomised kidneys, and prompt treatment with antifungal medication, including Amphotericin-B and posaconazole is necessary to save from otherwise fatal infection. Expand
Fungal endophthalmitis
  • J. Chhablani
  • Medicine
  • Expert review of anti-infective therapy
  • 2011
This review evaluates the current literature on FE and focuses on antifungal agents and discusses species-specific management and outcomes of FE. Expand
Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation.
A series of novel antifungal carboline derivatives was designed and synthesized, which showed broad-spectrum antIFungal activity and preliminary mechanism studies revealed that C38 might act by inhibiting the synthesis of fungal cell wall. Expand
Infection at diagnosis—a unique challenge in acute myeloid leukemia treatment in developing world
It is proposed that infection at baseline is to be considered as one of the potential variables in the predictive scoring system for induction mortality in developing countries. Expand